The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization for Merck and Ridgeback Therapeutics’ molnupiravir (to be trademarked LAGEVRIO in the UK). Results from an interim analysis from the Phase III MOVe-OUT clinical trial showed that the oral treatment could halve the risk of hospitalization or death for adults with a positive SARS-CoV-2 diagnostic test and mild to moderate COVID symptoms and who had at least one risk factor have at least one risk factor for developing severe illness.
The approval is ”a major achievement in Merck’s singular legacy of bringing forward breakthrough medicines and vaccines to address the world’s greatest health challenges,“ said Robert M. Davis, the company’s chief executive officer and president.
Wendy Holman, chief executive officer of Ridgeback Biotherapeutics, commented: ”It is also gratifying to see the first global authorization occur in the UK, the very place where we administered molnupiravir to the first brave human volunteer.”
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.